Cargando…

Antibody response to first BNT162b2 dose in previously SARS-CoV-2-infected individuals

Detalles Bibliográficos
Autores principales:	Manisty, Charlotte, Otter, Ashley D, Treibel, Thomas A, McKnight, Áine, Altmann, Daniel M, Brooks, Timothy, Noursadeghi, Mahdad, Boyton, Rosemary J, Semper, Amanda, Moon, James C
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier Ltd. 2021
Materias:	Correspondence
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7972310/ https://www.ncbi.nlm.nih.gov/pubmed/33640038 http://dx.doi.org/10.1016/S0140-6736(21)00501-8

Ejemplares similares

Persistent symptoms after COVID-19 are not associated with differential SARS-CoV-2 antibody or T cell immunity
por: Altmann, Daniel M., et al.
Publicado: (2023)

Prior SARS-CoV-2 infection rescues B and T cell responses to variants after first vaccine dose
por: Reynolds, Catherine J., et al.
Publicado: (2021)

Quantitative, multiplexed, targeted proteomics for ascertaining variant specific SARS-CoV-2 antibody response
por: Doykov, Ivan, et al.
Publicado: (2022)

Heterologous infection and vaccination shapes immunity against SARS-CoV-2 variants
por: Reynolds, Catherine J., et al.
Publicado: (2022)

Time series analysis and mechanistic modelling of heterogeneity and sero-reversion in antibody responses to mild SARS‑CoV-2 infection
por: Manisty, Charlotte, et al.
Publicado: (2021)

Asymptomatic health-care worker screening during the COVID-19 pandemic – Authors' reply
por: Treibel, Thomas A, et al.
Publicado: (2020)

COVID-19: PCR screening of asymptomatic health-care workers at London hospital
por: Treibel, Thomas A, et al.
Publicado: (2020)

HLA‐DR polymorphism in SARS‐CoV‐2 infection and susceptibility to symptomatic COVID‐19
por: Astbury, Stuart, et al.
Publicado: (2022)

Large clones of pre-existing T cells drive early immunity against SARS-COV-2 and LCMV infection
por: Milighetti, Martina, et al.
Publicado: (2023)

Longitudinal assessment of symptoms and risk of SARS-CoV-2 infection in healthcare workers across 5 hospitals to understand ethnic differences in infection risk.
por: Valdes, Ana M., et al.
Publicado: (2021)

Effect of previous SARS-CoV-2 infection on humoral and T-cell responses to single-dose BNT162b2 vaccine
por: Prendecki, Maria, et al.
Publicado: (2021)

Blood transcriptional biomarkers of acute viral infection for detection of pre-symptomatic SARS-CoV-2 infection: a nested, case-control diagnostic accuracy study
por: Gupta, Rishi K, et al.
Publicado: (2021)

Plasma proteomic signature predicts who will get persistent symptoms following SARS-CoV-2 infection
por: Captur, Gabriella, et al.
Publicado: (2022)

Neutralizing Activity of BNT162b2-Elicited Serum
por: Liu, Yang, et al.
Publicado: (2021)

Rapid synchronous type 1 IFN and virus-specific T cell responses characterize first wave non-severe SARS-CoV-2 infections
por: Chandran, Aneesh, et al.
Publicado: (2022)

Myocarditis after BNT162b2 Vaccination in Israeli Adolescents
por: Mevorach, Dror, et al.
Publicado: (2022)

Myocarditis after BNT162b2 Vaccination in Israeli Adolescents
por: Witberg, Guy, et al.
Publicado: (2022)

Effectiveness of BNT162b2 Vaccine against Delta Variant in Adolescents
por: Reis, Ben Y., et al.
Publicado: (2021)

Breakthrough Infections in BNT162b2-Vaccinated Health Care Workers
por: Lange, Bettina, et al.
Publicado: (2021)

Effectiveness of mRNA-1273 and BNT162b2 Vaccines in Qatar
por: Abu-Raddad, Laith J., et al.
Publicado: (2022)

CoronaVac or BNT162b2 Vaccine as a Third Dose
por: Mungmunpuntipantip, Rujittika, et al.
Publicado: (2022)

The second dose of the BNT162b2 mRNA vaccine does not boost SARS-CoV-2 neutralizing antibody response in previously infected subjects
por: Vicenti, Ilaria, et al.
Publicado: (2021)

SARS-CoV-2 Neutralization with BNT162b2 Vaccine Dose 3
por: Falsey, Ann R., et al.
Publicado: (2021)

Delayed second dose of the BNT162b2 vaccine: innovation or misguided conjecture?
por: Robertson, John F R, et al.
Publicado: (2021)

Immunogenicity of a BNT162b2 vaccine booster in health-care workers
por: Saiag, Esther, et al.
Publicado: (2021)

Effectiveness of BNT162b2 Vaccine against Omicron Variant in South Africa
por: Collie, Shirley, et al.
Publicado: (2021)

Third BNT162b2 Vaccination Neutralization of SARS-CoV-2 Omicron Infection
por: Nemet, Ital, et al.
Publicado: (2021)

Comparison of Waning Immunity Between Booster Vaccination and 2-Dose Vaccination With BNT162b2
por: Jung, Jiwon, et al.
Publicado: (2022)

BNT162b2 antigen dose and SARS-CoV-2 omicron infection in adolescents
por: Chemaitelly, Hiam, et al.
Publicado: (2023)

Temporal relation between second dose BNT162b2 mRNA Covid-19 vaccine and cardiac involvement in a patient with previous SARS-COV-2 infection
por: Ammirati, Enrico, et al.
Publicado: (2021)

Antibody response after second BNT162b2 dose in allogeneic HSCT recipients
por: Redjoul, Rabah, et al.
Publicado: (2021)

Effectiveness and Durability of the BNT162b2 Vaccine against Omicron Sublineages in South Africa
por: Collie, Shirley, et al.
Publicado: (2022)

BNT162b2-Elicited Neutralization against New SARS-CoV-2 Spike Variants
por: Liu, Yang, et al.
Publicado: (2021)

Long-term Antibody Response to the BNT162b2 Vaccine Among Maintenance Hemodialysis Patients
por: Nacasch, Naomi, et al.
Publicado: (2022)

Early humoral response among lung transplant recipients vaccinated with BNT162b2 vaccine
por: Shostak, Yael, et al.
Publicado: (2021)

Six-Month Follow-up after a Fourth BNT162b2 Vaccine Dose
por: Canetti, Michal, et al.
Publicado: (2022)

Reply to Mungmunpuntipantip and Wiwanitkit: CoronaVac or BNT162b2 Vaccine as a Third Dose
por: Mok, Chris Ka Pun, et al.
Publicado: (2022)

Effectiveness of Ad26.COV2.S and BNT162b2 Vaccines against Omicron Variant in South Africa
por: Gray, Glenda, et al.
Publicado: (2022)

BNT162b2 mRNA Covid-19 Vaccine Effectiveness among Health Care Workers
por: Benenson, Shmuel, et al.
Publicado: (2021)

Neutrophilic urticarial dermatosis following BNT162b2 (Pfizer–BioNTech) COVID‐19 vaccination
por: Matsubara, Akihiro, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_15dmopmec6uv1o8djh9mavdhls